Our business strategy is to create value for our stakeholders by promoting access to medicines through building robust product portfolios that achieve organic growth and by leveraging our world-class manufacturing capacities and capabilities. We seek to achieve this by building a differentiated portfolio of relevant IP, creating value through our complex manufacturing capabilities and enabling access through our globally integrated supply chain.
Our market positioning is focused on opportunities presented by emerging markets, balanced with presence in more established, stable developed markets. Through our dynamic portfolio management model, we build, optimise and reshape our basket of products to achieve a global product portfolio of niche, specialty products complemented by leading regional brands, aligned to our manufacturing capability.
We have proven manufacturing capability and capacity, creating access and sustainability collaboration opportunities for multinationals.
Committed management
team
aligned with
shareholder interests
Decentralised in-country structures enable local teams to operate with entrepreneurial flair, creating value by applying local experience
12,9% Shareholding by executive directors
Committed management
team
aligned with
shareholder interests
Decentralised in-country structures enable local teams to operate with entrepreneurial flair, creating value by applying local experience
17% Shareholding by executive management
A purpose-driven strategy with the promotion of access to medicine at its core
Manufactured 225 million COVID vaccines, signed an African vaccine access agreement with Serum Institute and a Human Insulin manufacturing agreement with Novo Nordisk A/S for Africa.
Supplied 210 medicines appearing on the Essential Medicines List to 60 low- to middle-income countries in FY2024
Consistent inclusion in the FTSE/JSE Responsible Investment Index since 2016 and member of the FTSE4GoodIndex
A purpose-driven strategy with
the promotion of access to medicine
at its core
Manufactured 225 million doses of COVID vaccines and signed a 10-year agreement with the Serum Institute of India Pvt Ltd (”Serum Institute”) promoting access to vaccines in Africa
Supplied 180 medicines medicines appearing on the Essential Medicines List to 60 low- to middle‑income countries
Consistent inclusion in the FTSE/JSE Responsible Investment index since 2016 and member of the FTSE4Good Index
Diverse product portfolio with strong brand equity supported by in-country commercial and sales employees
247
different product categories in the OTC portfolio
1 675
commercial and sales employees in emerging markets
342
commercial and sales employees in developed markets
101
product categories in the Injectables portfolio
325
different product categories in the medical prescription (Rx) portfolio
Commercial Pharmaceuticals portfolio supported by a global footprint, weighted towards emerging markets that benefit from economic and demographic growth fundamentals
Strong financial position with headroom to invest in the Commercial Pharmaceuticals portfolio, inherent to Portfolio management model
Leverage ratio below 3.5x covenant and below internal cap of 3x
Widely accredited and compliant API and FDF manufacturing capabilities with increasing focus on complex sterile capacities
Strategically relevant manufacturing capacities to deliver accelerated growth
* Dependent on regulatory timelines.
Sterile manufacturing
capabilities
Ampoules
Blow-fill seals
Polyamps
Eye drops
Lyophilized products
Prefilled syringes
Vials/ Cartridges
Sterile treatment
classes and therapies
Anaesthetics
Diabetes/ GLP-1s
Thrombosis
Flu vaccines
| Firm | Analyst | Contact Details | |
|---|---|---|---|
|
Covering Analyst |
ABSA |
Rendani Magalela |
rendani.magalela@absa.africa |
|
Covering Analyst |
HSBC |
Raj Sinha |
raj.sinha@hsbc.com |
|
Covering Analyst |
JPM |
Alex Comer |
alex.r.comer@jpmorgan.com |
|
Covering Analyst |
Nedbank |
Luyanda Njilo |
luyandan@nedbank.co.za |
|
Covering Analyst |
RMBMS |
Roy Campbell |
roy.campbell@rmbmorganstanley.com |
|
Covering Analyst |
Standard Bank |
Anuja Joshi |
anujajoshi@sbgsecuritiescom |
